Back to Authors

Lundgreen, Carly S.

https://orcid.org/0000-0002-1843-0493

Mayo Clinic

Mayo Clinic

Citations 2

NCMP-29. The risk for cognitive impairment differs in male and female cancer survivors
Neth, Bryan J. , Lundgreen, Carly S. , Syrjanen, Jeremy A. , Ruddy, Kathryn J. , Childs, Dan, Alden, Eva , Kevin, Nead, Botha, Hugo, Dasari, Surendra , Jack, Clifford R. , Petersen, Ronald , Graff-Radford, Jonathan, Neth, Byran J. , Jack, Clifford R , Childs, Dan, Botha, Hugo , Ramanan, Vijay K. , McCarter, Stuart J. , Sener, Uğur , Knopman, David S. , Vemuri, Prashanthi , Wefel, Jeffrey S. , Graff‐Radford, Jonathan

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v318-v318

10.1093/neuonc/noaf201.1258 Get It

Abstract BACKGROUND Understanding long-term sequelae of cancer care is critical. Cognitive impairment is a common and disabling survivorship issue. Because sex influences tumor biology, therapy exposure, and dementia risk, we examined whether cancer care for a prior malignancy alters late-life cognitive outcomes differently in males and females. METHODS We assessed adults ≥50 years, cognitively normal at study entry, from a longitudinal, population-based cohort (Mayo Clinic Study of Aging). Participants were linked to our institutional cancer registry (excluding non-melanoma skin cancers). Mild cognitive impairment (MCI) and dementia were adjudicated by consensus. We fitted multivariable Cox proportional-hazards models to estimate how prevalent cancer diagnosis influenced the risk of developing MCI/dementia. Sex-specific effects were determined by incorporating a cancer×sex interaction term and by generating separate hazard ratios. Analyses were controlled for age, APOE4 status, education, and presence of vascular/metabolic conditions. RESULTS 5793 MCSA participants (female: 49.4%, APOE4 positive: 27.5%) were included in the study, with a mean age of 73 years at study entry. Incident MCI was recorded in 866 participants, and 737 were diagnosed with incident dementia. About 20% (n=1176) of the cohort had a cancer diagnosis, most commonly prostate (n=423) and breast (n=277). There was no independent relationship between history of cancer and risk for MCI or dementia. We found that males with cancer had an increased risk for MCI (HR 1.28, 95% CI 1.04-1.57, p=0.003) and dementia (HR 1.29, 95% CI 1.04-1.6, p=0.053). Conversely, females with cancer had a lower risk for MCI (HR 0.79, 95% CI 0.61-1.01, p=0.063), although this was not statistically significant. CONCLUSIONS Our data suggests male cancer survivors may be more susceptible to cognitive impairment, independent of age, APOE4 status, education, and vascular/metabolic burden. Elucidating the hormonal, treatment-related, and systemic pathways driving this should be a priority for future mechanistic studies.